GT Apeiron

Apeiron Therapeutics intends to develop breakthrough investigational medicines by harnessing the power of artificial intelligence which drastically increases efficiency throughout the drug discovery process, from target selection, hit identification, lead optimization to pre-clinical studies and clinical trials.

GT Apeiron is strategically based in Shanghai and in the San Francisco Bay Area, with significant collaborations in the UK enabling us to tap into technologies and talent from all three continents.

Learn more

Latest News

Please follow our News page to learn about recent updates

Our Team

Our team and partners bring together deep expertise in applied AI and drug discovery to enable efficient and scalable discovery and development of novel drugs.


GT Apeiron is working with its partners to accelerate the R&D process to rapidly and efficiently deliver breakthrough therapies to patients across the globe.